Infection Risk Associated with Low Dose Rituximab in Primary Autoimmune Hemolytic Anaemia: Mechanisms, Outcomes, and Clinical Management

Authors

  • Ayman Fathy Arafa, Ahmed Mohamed Mansour Mohamed, Hassan Mahmoud Hassanin, Elsayed Anany Metwally

Keywords:

Infection Risk , Primary Autoimmune Hemolytic Anaemia, Rituximab

Abstract

Primary autoimmune hemolytic anaemia (AIHA) is a rare, potentially life-threatening disordercharacterized by immune-mediated destruction of red blood cells. Management of AIHA has evolved with theintroduction of monoclonal antibodies such as rituximab, which targets CD20-positive B lymphocytes, playing 

References

Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670.

Jäger U, D'Sa S, Schörgenhofer C, et al. Rituximab in the treatment of autoimmune hemolytic anemia: Results from a prospective trial with long-term follow-up. Hematol Oncol. 2019;37(4):379-385.

Downloads

Published

2024-06-20

How to Cite

Ayman Fathy Arafa, Ahmed Mohamed Mansour Mohamed, Hassan Mahmoud Hassanin, Elsayed Anany Metwally. (2024). Infection Risk Associated with Low Dose Rituximab in Primary Autoimmune Hemolytic Anaemia: Mechanisms, Outcomes, and Clinical Management. Journal of Computational Analysis and Applications (JoCAAA), 33(06), 2271–2284. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3299

Issue

Vol. 33 No. 06 (2024): JOCAAA

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.